Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutic Solutions International (TSOI) announced on September 10, 2021, the engagement of Venvalo Group to manage regulatory and strategic aspects of its FDA-cleared Phase III clinical trial for JadiCells, aimed at treating advanced COVID-19. Principal Investigator Dr. Camillo Ricordi praised the collaboration, citing prior successful trials with a 100% survival rate for patients under 85. CEO Timothy Dixon expressed excitement about leveraging expertise for effective clinical translation and developing an Emergency Use Application.
Therapeutic Solutions International (OTC: TSOI) announced a memorandum of understanding with Eutilogics, a subsidiary of Eutilex Co., Ltd., to explore technology synergies in immunotherapy. Eutilogics has developed an innovative autologous immunotherapy targeting tumors by activating T cells, while Therapeutic Solutions has filed an Investigational New Drug application for its StemVacs-V treatment aimed at targeting tumor blood vessels in breast cancer. Both companies aim to enhance treatment options, leveraging unique expertise to advance cancer therapies more rapidly.
Therapeutic Solutions International (OTC Markets: TSOI) announced the addition of stem cell expert Francisco Silva to its Scientific Advisory Board. Silva, a leader in clinical stem cell development, currently serves as Vice President of Research and Development at BioRestorative Therapies. His expertise is expected to enhance TSOI's therapeutic pipeline, particularly in regenerative medicine and COVID-19 treatments. TSOI is in discussions for partnerships to develop its JadiCell™ technology, which has shown high efficacy in clinical trials for COVID-19 patients.
Therapeutic Solutions International (OTC Markets: TSOI) announced promising preclinical results using JadiCells™ for treating COPD. In animal studies, JadiCells™ significantly reduced lung damage compared to traditional stem cells and enhanced anti-inflammatory responses. The company is pursuing further exploration of these cells, considering a new IND application. Following successful outcomes in treating COVID-19 patients, TSOI aims to fortify its intellectual property while identifying optimal indications for JadiCells™ development.
Therapeutic Solutions International (OTC: TSOI) announced that Dr. Peter C. Farrell joined the Advisory Board of its spin-off, Campbell Neurosciences, focused on suicide as a biological disorder. The company reported promising results from its Campbell Score® blood test, which predicts suicidal ideation. Dr. Farrell, an established leader in medical technology, is expected to enhance the company's strategic direction. Campbell, previously a division of Therapeutic Solutions, is now an independent biotech poised for growth in the mental health domain.
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) has appointed Dr. Boris Reznik to its Advisory Board to enhance the FDA-cleared Phase III JadiCell™ COVID-19 clinical trial. Dr. Reznik brings extensive experience in drug and device development, having successfully contributed to various biotech ventures. The clinical trial results for JadiCell™ show a 100% survival rate for COVID-19 patients under 85 and 91% for those over 85. This recruitment aims to leverage Dr. Reznik's expertise to optimize value in ongoing therapeutic developments.
Therapeutic Solutions International (OTC Markets: TSOI) announced a patent application revealing a novel mechanism of action for its JadiCell™ universal donor stem cell in treating advanced lung inflammation, akin to Delta Variant infection. Research indicated that JadiCell™ administration increased CD73 expressing T cells, crucial for its efficacy. Additionally, low-dose interleukin-2 enhanced JadiCell™'s protective effect against lung inflammation. The company's strategy emphasizes understanding therapeutic mechanisms, potentially leading to strategic partnerships and commercialization opportunities.
Therapeutic Solutions International (OTC: TSOI) has initiated preparations for an Emergency Use Authorization (EUA) to the FDA for its JadiCells™ therapy aimed at treating lung injuries related to COVID-19. The EUA enables the use of unapproved medical products during public health emergencies. The company reports promising preclinical data and recently received FDA clearance for a Phase III trial, where JadiCells™ showed 100% efficacy in saving lives of COVID-19 ICU patients below 85. Experts from its advisory board are facilitating fast-track approval processes.
Therapeutic Solutions International, Inc. (TSOI) announced significant findings regarding its JadiCell™ adult stem cells, indicating their superior capacity to promote neurogenesis compared to other stem cell types in inflammatory conditions. The research, linked to potential COVID-19 treatments, showed JadiCells were effective in stimulating brain cell production while other stem cells were not. Notably, in a clinical trial, JadiCell™ demonstrated a 100% survival rate for COVID-19 patients under 85 years. The company is advancing toward Phase I/II and Phase III trials for CTE and COVID-19 treatments, respectively.
Therapeutic Solutions International (OTC: TSOI) has completed FDA-requested preclinical experiments to initiate Phase I/II clinical trials for JadiCell™ treatment of chronic traumatic encephalopathy (CTE). This marks a significant milestone as TSOI holds the sole Investigational New Drug application for CTE. The FDA's acceptance of their CTE definition for living patients is viewed as a breakthrough. TSOI aims to leverage insights from ongoing COVID-19 trials to enhance treatment for CTE, addressing a critical medical need for athletes and military veterans.